These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10146746)

  • 1. Where is radiotherapy for stage C prostate cancer headed?
    Hanks GE
    Contemp Urol; 1994 Mar; 6(3):11-4. PubMed ID: 10146746
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proton hypophysectomy and subtotal body irradiation in combined treatment of stage IV prostate cancer].
    Aleksandrov VP; Kondrat'eva EA; Karelin MI; Konnov BA; Zharinov GM; Metelev VV; Pecherskiĭ AV
    Urologiia; 1999; (6):26-8. PubMed ID: 16859000
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: non-metastatic.
    Wilt T
    Clin Evid; 2002 Jun; (7):812-23. PubMed ID: 12230707
    [No Abstract]   [Full Text] [Related]  

  • 4. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
    Matveev BP; Bukharkin BV
    Urologiia; 2003; (6):6-10. PubMed ID: 14708235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of androgen suppression in prostate cancer.
    Badiozamani KR
    N Engl J Med; 2009 Sep; 361(12):1212; author reply 1212-3. PubMed ID: 19759384
    [No Abstract]   [Full Text] [Related]  

  • 6. [Endocrine therapy for localized or locally advanced prostate cancer].
    Fontaine E; Ruffion A; Staerman F
    Prog Urol; 2004 Jun; 14(3):433-6. PubMed ID: 15373195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    D'Amico AV
    J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901
    [No Abstract]   [Full Text] [Related]  

  • 10. This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.
    Yossepowitch O
    Eur Urol; 2007 Aug; 52(2):453. PubMed ID: 17674435
    [No Abstract]   [Full Text] [Related]  

  • 11. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 12. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A combination treatment for localized prostate cancer.
    Mayo Clin Health Lett; 2005 Feb; 23(2):4. PubMed ID: 15732168
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-only not dead?
    Chuba PJ; Aref A
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):329-30. PubMed ID: 16377423
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
    Woodward WA; Wachsberger P; Burd R; Dicker AP
    Prostate Cancer Prostatic Dis; 2005; 8(2):127-32. PubMed ID: 15643450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
    Bolla M; Maingon P; Fourneret P; Artignan X; Descotes JL
    Cancer Radiother; 2005 Nov; 9(6-7):394-8. PubMed ID: 16226044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
    Tauveron I; Hermabessière J
    Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
    [No Abstract]   [Full Text] [Related]  

  • 19. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?
    Miyamoto H; Messing EM; Chang C
    Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.